In parallel, immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) have revolutionized the treatment landscape for many types of cancers including non-small cell lung (NSCLC)4. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.